ascopubs.org

An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO ...

Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk ...
Nasdaq

Ipsen: New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx® in Combination with Opdivo® Showed Significantly Improved QoL Benefits and Sustained Superior ...

PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of new analyses from the pivotal Phase III CheckMate -9ER trial demonstrating ...
The American Journal of Managed Care

After More Than 3 Years, Nivolumab With Cabozantinib Shows Sustained Response Over Sunitinib in RCC

Long-term results show sustained benefit from the immunotherapy-TKI combination for patients with metastatic renal cell carcinoma regardless of risk profile or PD-L1 status. Patients receiving ...
Nasdaq

Exelixis Reports Positive Data From Post-hoc Exploratory Analysis Of Phase 3 CheckMate -9ER Trial

(RTTNews) - Exelixis, Inc. (EXEL) said data from a post-hoc exploratory analysis of the phase 3 CheckMate -9ER pivotal trial demonstrated efficacy benefits regardless of prior nephrectomy status with ...